THERAPY DOSSIER · th-3252f376f477

CBLB502 (entolimod)

Biologic · Recombinant flagellin-derived TLR5 agonist (biologic; not in ChEMBL).

Evidence & regulatory context

Mechanism: Recombinant flagellin-derived TLR5 agonist (biologic; not in ChEMBL).
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: entolimod; CBLB502
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01527136 ↗PHASE1completed

CBLB502 (Entolimod) Safety/PK in Patients With Advanced Cancers

Advanced Solid Tumor

Enrolment: 25 · Results not recorded

NCT03063736 ↗EARLY_PHASE1completed

Entolimod, an Adjuvant for Vaccine Augmentation

Substance Use Disorders

Enrolment: 40 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30084935 ↗2019Reported benefit

CBLB502, a Toll-like receptor 5 agonist, offers protection against radiation-induced male reproductive system damage in mice.

MouseRadiationC57BL/6; Tlr5 knockoutMaleIntraperitoneal0.2 mg/kg30 min before irradiation

Model: Whole-body ionising radiation at 5.0 Gy causing testicular injury

CBLB502 pre-treatment reduced radiation-induced oxidative stress, preserved seminiferous tubule architecture, sperm quantity and quality and fertility, lowered DNA damage and chromosomal aberrations, and reversed changes in testosterone, superoxide dismutase and malondialdehyde. Protection was abse…

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…